i do not want to get anyones hopes up unecessarily but given the discussion about NHS funding and the lack of access to Dasatinib within certain PCT's (i.e Newcastle-see posts below) i will take this opportunity to announce that our recent campaign to get NICE to consider Dasatinib as a Topic for NICE appraisal may have had some effect.
we have heard that Dasatinib and Nilotinib were being considered by the Topic Selection Consideration Panel (Cancer) and that this panel were supportive of the proposal that these drugs be appraised
and have been formally informed by the Topic Selection Manager (NICE) that both drugs have now been forwarded by the above panel for further consideration by the 'Referral Oversight Group'. This group determines the final list of topics to be recommended to the Minister for referral to NICE.
we consider this to be a very positive step towards solving the problem of certain pct's refusing to fund alternative drugs for Glivec resistance and we are cautiously hopeful of a positive outcom, hopefully in the not too distant future!
David Cornes and myself made great efforts to find and then lobby the various govnmt. bodies involved. targetting the correct panels and committees proved to be a challenge but we seem to have had some success, more than our MP's had i must admit.
thank you David for taking the time to help me draft the letters on behalf of CML Support.
sandy C ;o)
